






KRISHZYME™

beta-N-Acetylglucosaminidase S (β-N-Acetylglucosaminidase S)

REF : KPGF-009

Ver 2.0

RIUO

RIUO	For Research & Industrial Use Only	REF	Catalog Number
	Store At	LOT	Batch Code
	Manufactured By		Biological Risk
	Expiry Date		Consult Operating Instructions


For Research and Industrial Use Only. Purchase does not include or carry the right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of KRISHGEN BioSystems is strictly prohibited.

REF KPGF-009

KRISHGEN BioSystems For US/Europe Customers: toll free +1(888)-970-0827 | tel +1(562)-568-5005
For Asia/India Customers: +91(22)-49198700
Email: sales1@krishgen.com | <http://www.krishgen.biz>

Product Description:

Endo-β-N-acetylglucosaminidase S (Endo S) cleaves the hydrolysis of the β(1-4) linkage between the two core GlcNAcs of asparagine linked biantennary complex-type glycans of IgG Fc regions. This endoglycosidase only deglycosylates IgG glycoforms and plays a central role in glycoengineering strategies for the development of IgG antibodies with improved therapeutic efficacy.




Krishzyme Endo S comes in a lyophilized format that is perfectly suitable for use in solution-based analyses. The target core for Krishzyme Endo S is IgG Asparagine-linked (N-linked) oligosaccharides (complex).

Like other KRISHZYME Glycosidases, Krishzyme Endo S is lyophilized for stability during shipment and storage. Its performance is outstanding -

- able to produce clean peaks with very high yields (as detected by HPLC),
- commonly used in drug development or other research that is highly focused on the use of human antibodies.

This endoglycosidase only deglycosylates IgG glycoforms and plays a central role in glycoengineering strategies for the development of IgG antibodies with improved therapeutic efficacy.



Product Size:

Cat No	Pack Size	Concentration
KPGF-009	10000 U / 50 ul 20000 U/ 100 ul	200,000 U/ml

Physical Form:

KRISHZYME™ Endo-β-Acetylglucosaminidase S is supplied in a lyophilized format at a concentration of 200,000 U/ml when reconstituted in 100 ul of dH₂O to get 20000 U / 100 ul Both native and denatured glycoproteins are compatible for cleaving.

Reagents Supplied:

The following reagents are supplied with this product:

Composition	Formula	Concentration
Assay Buffer 1	50 mM CaCl ₂ , 500 mM Sodium Acetate, pH 5.5 at 25°C	10X

Product Source:

Recombinant enzyme expressed in E.coli.

Product Quality:

≥95% purity, as determined by SDS-PAGE. No other exoglycosidase, endoglycosidase, and protease activity were contaminated.

Unit Definition:

One unit is defined as the amount of enzyme required to completely deglycosylate 10 ug of denatured IgG following incubation for 60 minutes at 37°C.

Storage Temperature:

Store at -20°C. Avoid multiple freeze-thaws.

Characteristic:

- Recombinant enzyme with no detectable endoglycosidase or other exoglycosidases contaminating activities
- ≥95% purity, as determined by SDS-PAGE
- Optimal activity and stability for up to 12 months
- Glycerol-free for optimal performance in HPLC and mass spectrometry analysis

Applications:

- Structural analysis of oligosaccharides
- Glycoprotein deglycosylation
- Removing heterogeneity from glycoproteins

Suggestions for Use:

- 1) Combine 1-100 ug of glycoprotein and H₂O (if necessary) in a total reaction volume of 8 ul.
- 2) Add 1 ul of 10X Assay Buffer 1 to make a 9 ul total reaction volume.
- 3) Add 1ul Endo-β-Acetylglucosaminidase, mix gently.
- 4) Incubate at 37°C for 1 hour.

Notes :

- The amount of exoglycosidase enzyme required varies when different substrates are used. Start with 1-2 ul for 1-100 ug of glycoprotein for one hour in a 10-25 ul reaction. If there is still undigested material, let the reaction go overnight.
- The reaction can be scaled up linearly.

References:

Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. ... F Maley, RB Trimble, AL Tarentino... - Analytical biochemistry, 1989 - Elsevier

Deglycosylation of asparagine-linked glycans by peptide: N-glycosidase F. ... AL Tarentino, CM Gomez, TH Plummer Jr - Biochemistry, 1985 - ACS Publications/

Demonstration of peptide: N-glycosidase F activity in endo-beta-N-acetylglucosaminidase F preparations. ... TH Plummer, JH Elder, S Alexander, AW Phelan... - Journal of Biological ..., 1984 - ASBMB

Glycosylation of Pichia pastoris -derived proteins. ... RK Bretthauer, FJ Castellino - Biotechnology and applied ..., 1999 - Wiley Online Library.

Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. ... JP Morello, A Salahpour, A Laperrière... - The Journal of ..., 2000 - Am Soc Clin Investig.

A monolithic PNGase F enzyme microreactor enabling glycan mass mapping of glycoproteins by mass spectrometry. ... AK Palm, MV Novotny - ... An International Journal Devoted to the ..., 2005 - Wiley Online Library.

Protein-protein interaction and not glycosylation determines the binding selectivity of heterodimers between the calcitonin receptor-like receptor and the ... S Hilaiet, SM Foord, FH Marshall, M Bouvier - Journal of Biological ..., 2001 - ASBMB

Purification and Structure-Function Analysis of Native, PNGase F-Treated, and Endo-. beta.-galactosidase-Treated CHIP28 Water Channels. AN Van Hoek, MC Wiener, JM Verbavatz, D Brown... - Biochemistry, 1995 - ACS Publications

Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour ... WJ Mawby, CH Holmes, DJ Anstee, FA Spring... - Biochemical ..., 1994 - biochemj.org

LIMITED WARRANTY

Krishgen Biosystems does not warrant against damages or defects arising in shipping or handling, or out of accident or improper or abnormal use of the Products; against defects in products or components not manufactured by Krishgen Biosystems, or against damages resulting from such non-Krishgen Biosystems made products or components. Krishgen Biosystems passes on to customer the warranty it received (if any) from the maker thereof of such non Krishgen made products or components. This warranty also does not apply to Products to which changes or modifications have been made or attempted by persons other than pursuant to written authorization by Krishgen Biosystems.

THIS WARRANTY IS EXCLUSIVE. The sole and exclusive obligation of Krishgen Biosystems shall be to repair or replace the defective Products in the manner and for the period provided above. Krishgen Biosystems shall not have any other obligation with respect to the Products or any part thereof, whether based on contract, tort, and strict liability or otherwise. Under no circumstances, whether based on this Limited Warranty or otherwise, shall Krishgen Biosystems be liable for incidental, special, or consequential damages.

This Limited Warranty states the entire obligation of Krishgen Biosystems with respect to the Products. If any part of this Limited Warranty is determined to be void or illegal, the remainder shall remain in full force and effect.

Krishgen Biosystems. 2025

THANK YOU FOR USING KRISHGEN PRODUCT!

KRISHGEN BIOSYSTEMS®, GENLISA®, DHARMAPLEX™, GENBULK™, GENLISA™, KRISHZYME®, KRISHZYME SIWFT®, KRISHGEN®, KRIBIOLISA®, KRISHPLEX®, TITANIUM®, QUALICHEK® are registered trademarks of KRISHGEN BIOSYSTEMS PRIVATE LIMITED. ©KRISHGEN BIOSYSTEMS. ALL RIGHTS RESERVED.

KRISHGEN BIOSYSTEMS | OUR REAGENTS | YOUR RESEARCH |